Report: Canopy Growth stock tumbles as quarterly loss exceeds estimates.. New CEO..“As I step into my role I am focused on achieving sustainable profitability while maximizing our ability to create value in the key markets” | Cannabis Law Report | Where to buy Skittles Moonrock online
Learn where to order CBD online. TOP QUALITY GRADE A++
Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.
👉 Click here to Visit our shop! 🛒
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) shares plummeted after the Ontario-headquartered cannabis producer reported a greater-than-forecast loss for the fiscal third quarter.
For the quarter ended December 31, 2024, Canopy reported a loss of C$121.9 million, down from C$216.8 million for the same period in 2023.
On a per-share basis, it posted a loss per share of C$1.11, an improvement from a loss per share of C$2.62 a year earlier but far more than the loss per share of C$0.38 expected by analysts.
Revenue fell 5% year-over-year to C$74.8 million, above estimates of C$69.2 million.
Canada’s cannabis net revenue was up 1% from the year-ago quarter at C$41 million. Medical cannabis revenue grew 16% as adult use declined 10% year-over-year.
International revenue grew 14% to C$12 million, with strong growth highlighted in Poland and Germany partially offset by a decrease in Australian medical sales and exiting US CBD sales earlier in the fiscal year.
Gross margins declined by 400 basis points to 32% attributed to costs related to the launch of Claybourne infused pre-rolls in Canada and increased indirect costs for its Storz & Bickel branded vaporizer devices.
It achieved an adjusted EBITDA loss of C$3 million, marking a 61% improvement year-over-year.
The company highlighted that Q3 marked its best adjusted EBITDA to date, driven by topline growth in its medical cannabis business and its Storz & Bickel brand, which grew its sales by 19% year-over-year during the quarter.
“Canopy Growth’s third quarter highlights that our business has the right ingredients for success, as demonstrated by the continued momentum in our medical cannabis businesses, Storz & Bickel, and the successful introduction of Claybourne infused pre-rolls in Canada,” Canopy Growth CEO Luc Mongeau said in a statement.
“As I step into my role as Chief Executive Officer, I am focused on achieving sustainable profitability while maximizing our ability to create value in the key markets and segments we serve.”
Canopy Growth’s US-listed shares fell 22.7% at US$2.78 shortly before Friday’s opening bell, mirroring its loss on the TSX.
Source
Leave a Reply
Want to join the discussion?Feel free to contribute!